Interpreting elevated liver blood test results through a genetic lens: A genome-wide association study.
chronic liver disease
genetics
personalized medicine
prognosis
risk stratification
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
19 Oct 2024
19 Oct 2024
Historique:
revised:
10
09
2024
received:
21
06
2024
accepted:
12
09
2024
medline:
19
10
2024
pubmed:
19
10
2024
entrez:
19
10
2024
Statut:
aheadofprint
Résumé
Individuals with genetic polymorphisms in UGT1A1 exhibit bilirubin levels that belie their risk of liver disease (Gilbert's syndrome) but it is not known if this phenomenon extends to other common liver blood tests (LBTs). A genome-wide association analysis of 10 LBTs was conducted using the UK biobank. Polygenic scores (PGS) were created from discordant loci (e.g. loci associated with the LBT but not associated with cirrhosis morbidity risk). Participants were assigned to a low, intermediate or high PGS for each LBT. A high PGS approximates Gilbert's syndrome (i.e. elevated LBT without an analogous increase in disease risk). The prognostic significance of an 'elevated' LBT-and how this differs by PGS-was assessed through competing risk survival analysis. This study included 157 005 and 166 871 participants for the discovery and validation phases, respectively. Elevated LBTs were more prevalent in the high versus low PGS group, yet the 10-year risk of cirrhosis morbidity was comparable. For example, in the low PGS group, 4.3% had an elevated gamma-glutamyltransferase (GGT) and the 10-year risk of cirrhosis morbidity was .45%. Conversely, in the high PGS group, 21.2% had an elevated GGT and the 10-year risk was .38%. Accordingly, the 10-year risk of cirrhosis morbidity for individuals with an elevated GGT was markedly different in the low vs. high group (4.2% vs. 1.2%; p < .001). Similar results were apparent for Fibrosis-4 index, total bilirubin, and platelet count. Variability in LBTs is influenced by genetic polymorphisms that have a neutral effect on disease risk. These findings have implications for interpreting elevated LBTs in clinical practice.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Individuals with genetic polymorphisms in UGT1A1 exhibit bilirubin levels that belie their risk of liver disease (Gilbert's syndrome) but it is not known if this phenomenon extends to other common liver blood tests (LBTs).
METHODS
METHODS
A genome-wide association analysis of 10 LBTs was conducted using the UK biobank. Polygenic scores (PGS) were created from discordant loci (e.g. loci associated with the LBT but not associated with cirrhosis morbidity risk). Participants were assigned to a low, intermediate or high PGS for each LBT. A high PGS approximates Gilbert's syndrome (i.e. elevated LBT without an analogous increase in disease risk). The prognostic significance of an 'elevated' LBT-and how this differs by PGS-was assessed through competing risk survival analysis.
RESULTS
RESULTS
This study included 157 005 and 166 871 participants for the discovery and validation phases, respectively. Elevated LBTs were more prevalent in the high versus low PGS group, yet the 10-year risk of cirrhosis morbidity was comparable. For example, in the low PGS group, 4.3% had an elevated gamma-glutamyltransferase (GGT) and the 10-year risk of cirrhosis morbidity was .45%. Conversely, in the high PGS group, 21.2% had an elevated GGT and the 10-year risk was .38%. Accordingly, the 10-year risk of cirrhosis morbidity for individuals with an elevated GGT was markedly different in the low vs. high group (4.2% vs. 1.2%; p < .001). Similar results were apparent for Fibrosis-4 index, total bilirubin, and platelet count.
CONCLUSION
CONCLUSIONS
Variability in LBTs is influenced by genetic polymorphisms that have a neutral effect on disease risk. These findings have implications for interpreting elevated LBTs in clinical practice.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : UK Research and Innovation
Organisme : MRF
Pays : United Kingdom
Informations de copyright
© 2024 The Author(s). Liver International published by John Wiley & Sons Ltd.
Références
Enroth S, Johansson A, Enroth SB, Gyllensten U. Strong effects of genetic and lifestyle factors on biomarker variation and use of personalised cut offs. Nat Commun. 2014;5:4684.
Kachuri L, Hoffman TJ, Jiang Y, et al. Genetically adjusted PSA levels for prostate screening. Nat Med. 2023;29:1412‐1423.
Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67:6‐19.
Buchell B, Hume R. Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol. 1999;14:960‐966.
Scutt P, Ban L, Card T, et al. Liver blood marker testing in UK primary care: a UK wide cohort study, 2004‐2016. BMJ Open. 2022;12:e058967. doi:10.1136/bmjopen-2021-058967
Donnan PT, McLernon D, Dillon JF, et al. Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record‐linkage population cohort study and decision analysis (ALFIE). Health Technol Assess. 2009;13:1‐134.
Lilford RJ, Bentham L, Girling A, et al. Birmingham and Lambeth liver evaluation testing strategies (BALLETS): a prospective cohort study. Health Technol Assess. 2013;17:i‐xiv.
Harman DJ, Ryder SD, James MW, et al. Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross‐sectional diagnostic study utility transient elastography. BMJ Open. 2015;5:e007516. doi:10.1136/bmjopen-2014-007516
Llip E, Iruzubieta P, Perello C, et al. High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. United European Gastroenterol J. 2021;9:892‐902.
Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex disease of middle and old age. PLoS Med. 2015;12:E1001779.
Fry D, Almond R, Moffat S, Gordon M, Singh P. UK biobank project. Companion document to accompany serum biomarker data. Version 1.0. 2019. https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/serum_biochemistry.pdf
Sheard SM, Nicholls R, Froggatt J. UK Biobank Haematology Data Companion Document. 2017. https://biobank.ndph.ox.ac.uk/showcase/ukb/docs/haematology.pdf
Choi SW, Mak TSH, O‐Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15:2759‐2772.
Austin PC, Fine JP. Practical recommendations for reporting Fine‐gray model analyses for competing risk data. Stat Med. 2017;36:4391‐4400.
Valenti L, Pelusi S, Bianco C, et al. Definition of healthy ranges for alanine aminotransferase levels: a 2021 update. Hepatol Commun. 2021;5:1824‐1832.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO); European Association for the Study of the Liver (EASL). EASL‐EASD‐EASO clinical practice guidelines on the management of metabolic dysfunction‐associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492‐542.
Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79:277‐286.
Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non‐alcoholic fatty liver disease. J Hepatol. 2019;71:371‐378.
Chalmers J, Wilkes E, Harris R, et al. Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. Frontline Gastroenterology. 2019;11:86‐92. doi:10.1136/flgastro-2019-101177
Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK‐PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67:1568‐1594.
Dillon JF, Miller MH, Robinson EM, et al. Intelligent liver function testing (iLFT): a trial of automated diagnosis and staging of liver disease in primary care. J Hepatol. 2019;71:699‐706.
Buch S, Stickel F, Trepo E, et al. A genome‐wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol‐related cirrhosis. Nat Genet. 2015;47:1443‐1448.
Vujkovic M, Ramdas S, Lorenz KM, et al. A multiancestry genome‐wide association study of unexplained chronic ALT elevation as a proxy for non‐alcoholic fatty liver disease with histological and radiological validation. Nat Genet. 2022;54:761‐771.
Buch S, Innes H, Lutz PL, et al. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol‐related cirrhosis: results from a genome‐wide case‐control study. Gut. 2023;72:381‐391.
Verweij N, Haas ME, Nielsen JB, et al. Germline mutations in CIDEB and protection against liver disease. N Engl J Med. 2022;387:332‐344.
Innes H, Morling JR, Buch S, Hamill V, Stickel F, Guha IN. Performance of routine risk scores for predicting cirrhosis‐related morbidity in the community. J Hepatol. 2022;77:365‐376.
Innes H. Genetic data not yet a “game‐changer” for predicting individualised hepatocellular carcinoma risk. J Hepatol. 2023;78:460‐462.
Gene Ontology Consortium, Aleksander SA, Balhoff J, et al. The gene ontology knowledgebase in 2023. Genetics. 2023;224:iyad031.
Fry A, Littlejohns TJ, Sudlowe C, et al. Comparison of sociodemographic and health related characteristics of UK biobank participants with those of the general population. Am J Epidemiol. 2017;186:1026‐1034.